Zoledronic

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 6602 publications

Bisphosphonate zoledronic acid blocks secretory autophagy and inhibits bone resorptive functions in osteoclasts.

Bisphosphonate zoledronic acid blocks secretory autophagy and inhibits bone resorptive functions in osteoclasts.

Journal: Autophagy

Published: June 19, 2026

Intraoperative Zoledronic Acid for Arthroscopic Rotator Cuff Repair Results in Distinct Circulating Micro-RNA Profiles Indicating Improved Tendon-to-Bone Healing.

Intraoperative Zoledronic Acid for Arthroscopic Rotator Cuff Repair Results in Distinct Circulating Micro-RNA Profiles Indicating Improved Tendon-to-Bone Healing.

Journal: The American journal of sports medicine

Published: June 19, 2026

Loss of Flotillin-2 enhances trastuzumab emtansine internalization and cytotoxicity by relieving negative regulation of HER2 internalization in HER2-amplified cancers.

Loss of Flotillin-2 enhances trastuzumab emtansine internalization and cytotoxicity by relieving negative regulation of HER2 internalization in HER2-amplified cancers.

Journal: bioRxiv : the preprint server for biology

Published: June 04, 2026

Denosumab versus bisphosphonates for the management of bone metastases originating from breast cancer: a systematic review and meta-analysis.

Denosumab versus bisphosphonates for the management of bone metastases originating from breast cancer: a systematic review and meta-analysis.

Journal: Future oncology (London, England)

Published: June 02, 2026

Is Zoledronic acid cost-saving in daily practice?

Is Zoledronic acid cost-saving in daily practice?

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: May 28, 2026

One and Done - Single-Dose Zoledronic Acid in Early-Stage Breast Cancer.

One and Done - Single-Dose Zoledronic Acid in Early-Stage Breast Cancer.

Journal: NEJM evidence

Published: May 26, 2026

Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer.

Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer.

Journal: NEJM evidence

Published: May 26, 2026

Analysing compliance with calcium and vitamin D supplementations in cancer patients receiving bone resorptive agents.

Analysing compliance with calcium and vitamin D supplementations in cancer patients receiving bone resorptive agents.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: May 25, 2026

Antacid Abuse - A Case of Milk-Alkali Syndrome.

Antacid Abuse - A Case of Milk-Alkali Syndrome.

Journal: Irish medical journal

Published: May 25, 2026

Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.

Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.

Journal: JAMA

Published: May 14, 2026

Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.

Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial.

Journal: JAMA

Published: May 14, 2026

Denosumab as Second-Line Treatment in Patients With Metastatic Breast Cancer: A Retrospective Descriptive Pilot Study From a Single Institution.

Denosumab as Second-Line Treatment in Patients With Metastatic Breast Cancer: A Retrospective Descriptive Pilot Study From a Single Institution.

Journal: Cancer control : journal of the Moffitt Cancer Center

Published: May 04, 2026

Showing 1-12 of 6,602

Last Updated: 06/30/2026